background:
The onset of the COVID-19 pandemic caused numerous difficulties in
the treatment of cardiovascular diseases and diabetes mellitus. A persistent risk of developing
severe complications and increased mortality from the COVID-19 infection has been reported.
In the clinical studies, patients receiving remdesivir and dexamethasone as COVID-19 combination
therapy simultaneously with some type II diabetes therapeutic regimens had been reported
to have a considerably better state and recover faster. Unfortunately, there is not enough
information on the combination of meglitinides, remdesivir, and dexamethasone, and therefore,
careful monitoring of the patients' everyday health condition is needed.
objective:
The present study aimed to describe a high-performance liquid chromatographic
method for the determination of repaglinide, dexamethasone, and remdesivir in laboratoryprepared
mixtures and human plasma by UV detection.
method:
Isocratic elution of the mobile phase (consisting of 0.1% trifluoroacetic acid in water
and acetonitrile in the ratio 70:30 v/v) was set at a flow rate of 1.0 ml/min, and the developed
analytical procedure has been found to be fast and simple. Chromatographic determination was
performed on a Purospher® RP – 18 column at room temperature and a UV detector was set at
235 nm.
result:
The developed method was validated for linearity in the range 2-32 μg/ml. Calibration
curves were linear over the selected range with correlation coefficients (R2) greater than 0.996.
The coefficients of variation for intraday and interday assay were <2% and the recovery percentages
from plasma ranged from 93.83 to 106.49%.
conclusion:
The developed effective and specific method can be applied in routine quality
control and clinical laboratory practice.